Last reviewed · How we verify

Revelise (GENERIUM, Russia) — Competitive Intelligence Brief

Revelise (GENERIUM, Russia) (Revelise (GENERIUM, Russia)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoietin-stimulating agent (ESA). Area: Hematology/Oncology.

phase 3 Erythropoietin-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology Biologic Live · refreshed every 30 min

Target snapshot

Revelise (GENERIUM, Russia) (Revelise (GENERIUM, Russia)) — AO GENERIUM. Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Revelise (GENERIUM, Russia) TARGET Revelise (GENERIUM, Russia) AO GENERIUM phase 3 Erythropoietin-stimulating agent (ESA) Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoietin-stimulating agent (ESA) class)

  1. AO GENERIUM · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Revelise (GENERIUM, Russia) — Competitive Intelligence Brief. https://druglandscape.com/ci/revelise-generium-russia. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: